Collectively, these findings underscore the pathological significance of PKMYT1 in CML and its potential as a therapeutic target for inhibiting tumor cell proliferation and promoting mitochondrial dysfunction. This evidence concerns the gene PKMYT1 and chronic myelogenous leukemia, BCR-ABL1 positive.